A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations.
The clinical utility of performing tumor genetic testing to assess for alterations beyond the known targetable oncogenes in lung adenocarcinoma is unclear. Analyzing cancer pathway alterations beyond single oncogenic driver mutations in addition to markers of tumor mutation burden and genomic instability may provide additional predictive and prognostic information.See related article by Zhou et al., p. 7475.